Sign In
Buy AYTU
$2.09
-0.0100 (-0.476%)
At Close: Jun 03, 2026
Aytu BioPharma, Inc. (AYTU) Q3 2024 Earnings Call Transcript
08:28pm, Wednesday, 15'th May 2024
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q3 2024 Earnings Call Transcript May 15, 2024 4:30 PM ET Company Participants Roger Weiss - Investor Relations Joshua Disbrow - Chief Executive Officer Mark Oki - C
Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results
04:05pm, Wednesday, 15'th May 2024
Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023 Q3 2024 adjusted EBITDA 1 improved by $7.0 million compared to Q3 2023 TTM March 2024 operating income of $7.3 million for the Rx Business
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
04:15pm, Wednesday, 08'th May 2024
DENVER, CO / ACCESSWIRE / May 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
09:00am, Wednesday, 03'rd Apr 2024
Webcasted presentation to take place at 4:40 p.m. Eastern time DENVER, CO / ACCESSWIRE / April 3, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused
Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript
10:52pm, Wednesday, 14'th Feb 2024
Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
04:05pm, Wednesday, 14'th Feb 2024
Q2 2024 operating income of $2.4 million Q2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 million Q2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
04:15pm, Wednesday, 07'th Feb 2024
DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its finan
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
09:00am, Tuesday, 23'rd Jan 2024
DENVER, CO / ACCESSWIRE / January 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Jo
Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023
08:00am, Thursday, 30'th Nov 2023
Webcasted presentation to take place at 1:10pm ET DENVER, CO / ACCESSWIRE / November 30, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commerci
Aytu BioPharma, Inc. (AYTU) Q1 2024 Earnings Call Transcript
07:30pm, Tuesday, 14'th Nov 2023
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q1 2024 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Robert Blum - IR Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants N
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
04:05pm, Tuesday, 14'th Nov 2023
Q1 2024 Adjusted EBITDA of $2.2 million Rx Segment net revenue of $17.8 million and Adjusted EBITDA of $2.4 million in Q1 2024 Q1 2024 ADHD net revenue up 31% compared to Q1 2023 $20.0 million cash ba
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year
08:30am, Wednesday, 08'th Nov 2023
Ranked 118th Fastest Growing Company in North America Ranked 23rd Fastest Growing Life Sciences Company DENVER, CO / ACCESSWIRE / November 8, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDA
Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023
04:15pm, Tuesday, 07'th Nov 2023
DENVER, CO / ACCESSWIRE / November 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial r
Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
08:00am, Thursday, 26'th Oct 2023
U.S. Food & Drug Administration Approval of the Prior Approval Supplement (PAS) Enables Transfer of Cotempla Production to Contract Manufacturer Upon Completion of Manufacturing Transfer of Adzenys XR
Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023
04:15pm, Monday, 09'th Oct 2023
ENGLEWOOD, CO / ACCESSWIRE / October 9, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that
